drugset / Trial / NCT03136406
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.
Timeline
- Start
- 2017-08-11
- Primary completion
- 2017-11-22
- Completion
- 2019-11-01
Outcome
Outcome not reported
Stopped: “Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | ETBX-011 | Vaccine | — | — |
| Subject | GI-4000 | Vaccine | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | aNK for Infusion | Cell therapy | — | — |
| Subject | fluorouracil | Small molecule | — | — |